Monopar Therapeutics

Monopar Therapeutics

Monopar Therapeutics was formed in 2014 by Chandler Robinson, a physician with an MBA from Northwestern, and incorporated in Delaware before securing an Illinois headquarters. The company was built to develop in-licensed therapeutic compounds, taking a deliberate path to the public markets with a 2019 IPO that raised roughly $9 million by pricing shares at $8.00 in December of that year (per Renaissance Capital, 2019). Robinson and co-founder Andrew Mazar, the firm's chief scientific officer, established a lean structure that outsources drug development to contract research organizations and academic collaborators rather than building internal laboratory infrastructure. The firm's strategy centers on advancing drug candidates through clinical trials for cancer and severe chemotherapy side effects, with a dual focus on late-stage prophylactic agents and radiopharmaceuticals. Its lead asset has historically been Validive, a clonidine-based mucobuccal tablet designed to prevent severe oral mucositis in patients undergoing chemoradiation for head and neck cancer, developed under a license from BioAlliance Pharma. The pipeline also includes Camsirubicin, a safer anthracycline analog for soft tissue sarcoma licensed from the University of Minnesota, and MNPR-101, a urokinase plasminogen activator receptor-targeting antibody for advanced solid tumors. Monopar operates almost exclusively in the United States and relies on licensing deals from European and Australian biotechs and academic institutions, supplementing its budget through at-the-market equity offerings and public follow-ons rather than venture capital rounds. Monopar's balance sheet relies on periodic public equity raises, with a cash runway typically extending 12 to 18 months between filings. The company reported near $7.3 million in cash in early 2024 after closing a $6 million public offering in January 2024 (per the firm's Form 8-K, January 2024). The team remained under 10 employees, pulling clinical and regulatory expertise through consulting agreements without fixed infrastructure. In June 2024, Monopar announced a 1-for-5 reverse stock split to maintain Nasdaq listing compliance, reflecting the capital constraints common to pre-revenue biotechs reliant on equity-linked dilution. No philanthropic or family-office adjacent structures have been disclosed. Monopar's public-micro-cap architecture diverges from the traditional venture-backed biotech model — it trades on Nasdaq under the ticker MNPR, letting retail and institutional investors fund clinical milestones through liquidity rather than private negotiations. This structure ties its pipeline directly to market sentiment, with no venture partners to syndicate risk and no family-office anchor to absorb volatility. The company's governance rests entirely with Robinson, who holds multiple roles across the enterprise.